Clinical Trial Update: Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the efficacy and safety of the triple-combination CFTR modulator elexacaftor/tezacaftor/ivacaftor in cystic fibrosis patients without…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Trikafta (elexacaftor/tezacaftor/ivacaftor) (elexacaftor/tezacaftor/ivacaftor)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 3 | Status: COMPLETED | Results posted: 2024-08-01